This scientific statement from the National Lipid Association recommends icosapent ethyl for cardiovascular risk reduction in select patients and is largely based on results of REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial). Evidence for this recommendation is newly available since finalization of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.

Read the Key Points